Form 4: SAB Biotherapeutics Chief Medical Officer Reports Stock Transaction

Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc., reported a transaction involving the withholding of common stock to cover tax obligations related to vested restricted stock units.

Summary

• Alexandra Kropotova, the Chief Medical Officer of SAB Biotherapeutics, Inc., filed a Form 4 indicating a transaction on December 18, 2024.
• The transaction involved the withholding of 9,072 shares of common stock to satisfy tax obligations related to the vesting of restricted stock units (RSUs).
• Following the transaction, Kropotova directly owns 48,428 shares of common stock.
• This includes 21,712 shares and 26,716 shares that are still subject to vesting under the company's 2021 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock transactions, and does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, as required by the Securities and Exchange Commission (SEC).
• The transaction is typical for executives who receive stock-based compensation, where a portion of shares are withheld to cover taxes upon vesting.
• Similar filings are regularly made by executives at comparable biotech companies such as Regeneron, Amgen, and Gilead Sciences.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a standard procedure for executive compensation.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, SAB Biotherapeutics, Stock Transaction, Restricted Stock Units, Equity Incentive Plan, Chief Medical Officer, Alexandra Kropotova, Tax Withholding